Tresiba FlexTouch

Tresiba FlexTouch is a long-acting insulin used to help control blood sugar levels in people with diabetes. Its active ingredient, insulin degludec, is prescribed for adults and children (≥1 year) with Type 1 or Type 2 diabetes.

Tresiba FlexTouch is a prefilled injection pen that delivers insulin under the skin. One key benefit of Tresiba FlexTouch is its ultra-long duration of action, lasting up to 42 hours, which helps reduce fluctuations in blood sugar.

Tresiba FlexTouch Pen is FDA-approved for once-daily use as part of a broader diabetes management plan. This plan may include mealtime insulin, regular physical activity, healthy eating, and regular blood sugar monitoring.

Tresiba FlexTouch Quick Facts

Always follow your healthcare provider’s instructions for proper insulin injection technique. Below is a general step-by-step guide for using the Tresiba FlexTouch pen:

• Check insulin: Make sure it’s the right type and clear.
• Attach new needle: Twist the needle onto the pen, remove both caps (keep the outer cap).
• Prime the pen: Follow the manufacturer's instructions.
• Select your dose: Turn the dial to your prescribed units.
• Inject dose: Insert the needle into your abdomen, thigh, or upper arm. Press and hold until “0” appears. Keep it in place for 6 seconds.
• Remove the needle: Recap with the outer cap, unscrew, and dispose of it in a sharp container. Put the pen cap back on.

Tresiba FlexTouch contains insulin degludec, a long-acting insulin. After injection under the skin, it forms stable multihexamers that create a slow-release depot, allowing insulin to be absorbed gradually over 24 hours or longer. Insulin degludec helps move glucose from the bloodstream into cells for energy. This steady, long-lasting action supports more consistent blood sugar control throughout the day and night, helping reduce fluctuations such as highs and lows.

• Do not share your Tresiba (insulin degludec) pen with others, even if the needle is changed. Sharing can spread infections.
• Never mix Tresiba with other insulins or transfer it to a syringe. It is not intended for intravenous (IV) use or for use in insulin pumps.
• Before using Tresiba, tell your doctor if you have:
  • Liver disease or liver impairment
  • Kidney disease or reduced kidney function
  • A history of severe low blood sugar (hypoglycemia)
  • Heart problems, high blood pressure, or circulation issues
  • Any recent illness, infection, or surgery that may affect blood sugar control
  • Are pregnant, planning pregnancy, or breastfeeding (insulin needs may change during pregnancy)
• Do not stop Tresiba suddenly without medical advice, as this could lead to uncontrolled blood sugar or diabetic ketoacidosis (DKA).
• Do not use Tresiba if you:
  • Are experiencing diabetic ketoacidosis (DKA) because this requires fast‑acting insulin and urgent medical treatment
  • Have an allergy to insulin degludec or any of its ingredients
• If you miss a Tresiba dose, take it as soon as you remember. Ensure at least 8 hours between doses. Do not double the dose the next day.
• Taking too much Tresiba may cause severe low blood sugar (hypoglycemia). If a Tresiba overdose is suspected or symptoms are severe or do not improve, seek medical help immediately or call Poison Control.
• Check your blood sugar regularly & follow your doctor’s instructions for dose adjustments.
• Rotate injection sites (abdomen, thigh, upper arm) to avoid skin thickening or pits.
• Store unused pens in the refrigerator. In‑use Tresiba pens can be kept at room temperature (below 30°C) for up to 8 weeks.

Patient Tips for Using Tresiba FlexTouch (Insulin Degludec)

Using Tresiba FlexTouch (insulin degludec) correctly can help you achieve more stable blood sugar control and reduce the risk of side effects. The following patient tips may help improve safety and effectiveness:

• Take Tresiba once daily as prescribed, preferably at the same time each day, even though it allows flexible timing.
• Never intentionally skip doses, as missing basal insulin can lead to uncontrolled blood sugar.
• Inform your healthcare provider about illness, stress, or changes in diet or activity, as insulin needs may change.
• Always use a new needle for each injection to ensure accurate dosing and reduce infection risk.

Tresiba FlexTouch (insulin degludec) can interact with several medications that affect blood sugar control. Always inform your doctor about all medicines you are taking, including over‑the‑counter drugs and supplements.

If Tresiba (insulin degludec) is not suitable, you may consider the following alternatives for Type 1 and Type 2 diabetes under medical supervision:

• Lantus (insulin glargine)
• Basaglar (insulin glargine)
• Levemir (insulin detemir)
• Toujeo (insulin glargine U‑300)
• Semglee (insulin glargine)

Which Is Better, Tresiba vs. Lantus?

Both are FDA‑approved long‑acting basal insulins for Type 1 and Type 2 diabetes. The “better” choice depends on your blood sugar needs, lifestyle, and cost considerations. Below is a comparison to help you understand the key differences between Tresiba and Lantus:

Choosing Polar Bear Meds allows U.S. patients to access Tresiba FlexTouch through a trusted network of licensed Canadian pharmacies.

• All medications are dispensed by licensed Canadian pharmacies to ensure authenticity and quality.
• Tresiba FlexTouch may cost up to 80-90% less than prices at many U.S. retail pharmacies.
• Orders are shipped safely from Canada to the U.S. with secure packaging and tracking.
• New customers may save 10% on their first order with the code WELCOMEPB10.
• Earn a $20 credit for each verified referral.
• A price match guarantee helps ensure competitive pricing.
• Customer support is available to assist with orders and prescriptions.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203314s018s020lbl.pdf

https://www.webmd.com/drugs/2/drug-170029/tresiba-flextouch-u-100-subcutaneous/details

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=456c5e87-3dfd-46fa-8ac0-c6128d4c97c6 https://www.mayoclinic.org/drugs-supplements/insulin-degludec-subcutaneous-route/description/drg-20155729

https://www.ema.europa.eu/en/documents/product-information/tresiba-epar-product-information_en.pdf